Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Corrigendum.
Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.
Multiple sclerosis-associated IL2RA polymorphism controls GM-CSF production in human TH cells.
ATX-MS-1467 in Multiple Sclerosis
Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.
Opexa Amends Agreement with Merck Serono and Receives Additional $3 Million Payment to Support Ongoing Development of Tcelna® for Multiple Sclerosis
A qualitative study of the childbearing experience of women living with multiple sclerosis.
Systemic treatment with the inhibitory neurotransmitter gamma-aminobutyric acid aggravates experimental autoimmune encephalomyelitis by affecting proinflammatory immune responses.
Lymphocytes with cytotoxic activity induce rapid microtubule axonal destabilization independently and before signs of neuronal death.
Massage therapy and exercise therapy in patients with multiple sclerosis: a randomized controlled pilot study.
Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review.
Decreased serum levels of nucleolin protein fragment, as analyzed by bead-based proteomic technology, in multiple sclerosis patients compared to controls.
Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis.
Diet, microbiota and autoimmune diseases.
Simvastatin affects cell motility and actin cytoskeleton distribution of microglia.
BREMSO: a simple score to predict early the natural course of multiple sclerosis.
A RARE CASE OF ODONTOGENIC PARAINFECTIOUS INTRAORBITAL OPTIC NEURITIS WITH THE ABSENCE OF CLINICAL MANIFESTATION OF ORBITAL CELLULITIS.
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.
Multiple Sclerosis: A Disease of Affluence?.
Interleukin-10 expression during the acute phase is a putative prerequisite for delayed viral elimination in a murine model for multiple sclerosis.
Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis.
Disease mechanisms in MS: A role for sodium channels in regulation of macrophage-mediated pathology in multiple sclerosis lesions.
Multiple sclerosis, blood flow, and CSF circulation.
Cyclophosphamide so-so verdict in progressive MS
Profile of Circulatory Metabolites in a Relapsing-remitting Animal Model of Multiple Sclerosis using Global Metabolomics.
Pages
« first
‹ previous
…
265
266
267
268
269
270
271
272
273
…
next ›
last »